Anemia in cancer patients is associated with reduced quality of life and local failure after radiation treatment. However, the use of erythropoietin to correct cancer anemia and to improve radiation efficacy was disappointing. Erythropoietin-receptor signaling mainly acts via activation of STAT 5, but also crossactivates the antiapoptotic transcription factor NF-jB. This causes neuroprotection against oxidative stress and implies radioprotection. In order to investigate possible radioprotective effects of erythropoietin-receptor signaling, we used an in vitro model system employing HeLa TetOff cells, stably transfected with an expression vector for the erythropoietin-receptor gene. Using electrophoretic mobility shift assays, we could demonstrate strong activation of NF-jB by erythropoietin-receptor signaling in HeLa cells. Activation of NF-jB did not require degradation of IjBa and was not prevented by proteasome inhibition. Furthermore, stimulation with erythropoietin resulted in a 50% increased clonogenicity of erythropoietin-receptor-expressing cells but did not alter radiation sensitivity itself. As most human tumors express erythropoietin receptor, we advocate a restricted use erythropoietin to patients suffering from erythropoietin-receptor-expressing cancers.
response Anemia is known to be a strong independent prognostic factor for local failure and cancer-specific survival after radiation treatment of cancer (Frommhold et al., 1998; Harrison et al., 2002) . In general, an increased proportion of hypoxic cells in tumors of anemic patientsexhibiting increased radiation resistance based on the theory of the oxygen enhancement ratio -has been attributed to be the major underlying mechanism for this clinical observation, but in vivo experiments could not show a radiosensitizing effect of increased hematocrit in anemic, tumor-bearing animals (Hirst et al., 1984; Hirst and Wood, 1987; Joiner et al., 1993) and data correlating hematocrit and the proportion of hypoxic cancer cells in a given tumor was inconclusive (Poskitt, 1987; Dunst et al., 2003) . Nevertheless, recombinant human erythropoietin (rhEpo) entered clinical trials to correct anemia in cancer patients and particularly to improve quality of life (Gabrilove et al., 2001; Littlewood et al., 2001; Fallowfield et al., 2002) and tumor control. However, in contrary to blood transfusions, cytokine treatment might be complicated by activation of important signal transduction pathways that interact with tumor cell response to cancer treatment.
The erythropoietin receptor (EpoR) is a transmembrane protein and belongs to the family of hemopoietin receptors. Binding of its ligand Epo causes dimerization of the receptor and subsequent activation of associated tyrosine kinases of the Jak family. This activates Map kinases and PI-3 kinase and causes activation of the transcription factor STAT5 and thus, activation of downstream signal transduction pathways and transcription of target genes (Damen and Krystal, 1996; Verdier et al., 1998) . Recently, crossactivation of the NF-kB pathway by EpoR signaling has been reported, which resulted in cyto-protection (Digicaylioglu and Lipton, 2001) . NF-kB is a hetero-or homodimeric transcription factor sequestered preformed in the cytoplasm by inhibitor molecules of the IkB family. Activation of this pathway is normally achieved by phosphorylation of one of the most important inhibitors, IkBa, at two serine sites by IkB kinases. This marks IkBa for polyubiquitination and subsequent degradation by the proteasome. Degradation of IkBa frees NF-kB for translocation to the nucleus and activation of its target genetic programs (Baeuerle and Baltimore, 1996) .
Recently, two phase III trials demonstrated decreased survival and decreased local control in patients with metastatic breast cancer undergoing chemotherapy (Leyland-Jones, 2003) or patients with cancer of the head and neck treated by radiation (Henke et al., 2003) . These unexpected results raise the question as to whether Epo may also modulate the response of tumor cells to cancer treatment.
In order to address this question, we developed an in vitro model system to examine the effect of Epo treatment on the radiation sensitivity of EpoR-expressing and EpoR-nonexpressing cervical cancer cells.
Validation of the inducible EpoR-expression system
To study the effects of the EpoR pathway on radiation and chemosensitivity of cancer cells, we established stable-transfected HeLa cell lines expressing a wild-type erythropoietin receptor under control of a tetracyclineresponsive element. Cells were permanently kept in selection media containing hygromycin B and G418. Genomic integration of the vector was verified by PCR amplification using specific primers, annealing to the tetracycline-responsive element of the promoter region of the pTre2-Vector and exon 7 (bp 863-882) of the EpoR gene, respectively, and genomic DNA as template. After 48 h of incubation in tetracycline-free media, inducible gene expression of the EpoR gene was confirmed by RT-PCR (Figure 1a ), leading to a 20-fold increase in EpoR protein levels when compared to tetracycline-treated controls (Figure 1b) . Externalization of the EpoR was confirmed by flow cytometry using an antibody against the extracellular domain of the human erythropoietin receptor (Figure 1c ). To demonstrate functional integrity of the transcript, STAT 5 was immune-precipitated from total cellular lysates. With decreasing tetracycline concentrations, Western blotting against phospho-tyrosine revealed increased amounts of tyrosine-phosphorylated STAT 5, indicating regulation of STAT 5 signal transduction by regulated gene expression of EpoR (Figure 1d ).
Crossactivation of NF-jB by the Epo/EpoR-signal transduction pathway
Crossactivation of the antiapoptotic transcription factor NF-kB and subsequent protection from oxidative stress have been reported for the Epo/EpoR pathway in normal tissues (Digicaylioglu and Lipton, 2001; Buemi et al., 2003; Calvillo et al., 2003) . Although several different groups reported expression of EpoR in tumor specimens (Acs et al., 2003; Ribatti et al., 2003) and established cell lines (Acs et al., 2001; Westphal et al., 2002) , the question of activation of the NF-kB pathway by the EpoR pathway in tumor cells has not been addressed yet. Western blot analysis using total cellular lysates from HeLa TetOff-EpoR cells 48 h after the start of incubation at tetracycline concentrations from 0 to 1 mg/ml. Total cellular lysates from EMSA experiments were boiled with twofold La¨mmli buffer for 5 min, subsequently separated by SDS gel electrophoresis (0.1% SDS/12.5% polyacrylamide) and blotted to PVDF membranes. Membranes were blocked in 5% skim milk. Western blotting was performed according to standard protocols using a polyclonal mouse antibody against EpoR (C-20, 1 : 5000, overnight incubation, Santa Cruz Biotechnology) and a polyclonal rabbit antibody against IkBa (1 : 2000, 2 h, BD Bioscience). Equity of loading was verified using a mouse monoclonal antibody against atubulin (1 : 5000, 2 h, Oncogene). Secondary HRP-conjugated antibodies and the ECLplus system (Amersham) were used for visualization. EpoR protein levels in cells maintained in tetracycline-free media (lane 9) increased more than 20-fold over baseline levels (lane 1). (c) Flow cytometric analysis of nontransfected HeLa cells (filled histogram) and HeLa TetOff-EpoR (open histogram) cells 48 h after the start of incubation in tetracycline-free media was performed to verify externalization of the induced EpoR gene product to the cell surface. In order to verify externalization of the induced EpoR gene product to the cell surface, cells were trypsinized, and incubated with a primary antibody against the extracellular domain of the human EpoR (rabbit-anti-human, H194, Santa Cruz Biotechnology Inc.) for 45 min on ice. Cells were washed three times in PBS and stained with an FITC-conjugated secondary antibody (goat-anti-rabbit, Jackson Immunoresearch, Dianova, Hamburg), washed twice in PBS (0.1% sodium-acid, 1% FCS) and analysed by flow cytometry (FACScalibur, Becton Dickinson GmbH, Germany) using the 'CellQuest' software (Becton Dickinson GmbH, Germany). (d) Immune precipitation of total cellular lysates from HeLa TetOff-EpoR cells after incubation at 100, 10, 1 and 0 ng/ml tetracycline for 48 h using an antibody against STAT 5. Cells were stimulated for 10 min with 25 I.U./ml rhEpo before protein extraction. Cells were lysed in RIPA buffer (50 mM Tris-HCl (pH 7.2), 150 mM NaCl, 1% Nonidet P-40, SDS, supplemented with sodium orthovanadate, PMFS and 1% protease inhibitor cocktail (P8340, Sigma)). Immune precipitation was performed according to standard protocols using a polyclonal antibody against STAT 5 (rabbit-anti-human, IgG, sc 1081, Santa Cruz, Heidelberg) and a polyclonal antibody against IkBa, respectively (rabbit-anti-human, BD Bioscience). For Western blots with anti-phospho-tyrosine antibodies, membranes were blocked in 5% BSA. Western blotting using an antibody against phospho-tyrosine showed an increased tyrosine phosphorylation with increased expression of EpoR. (e) EMSA using 15 mg total cellular lysates from HeLa TetOff-EpoR cells 48 h after the start of incubation at tetracycline concentrations from 0 to 1 mg/ml. EMSA's were performed as described in Pajonk et al. (1999) . All cells received Epo (25 U/ml). EpoR signaling crossactivated the NF-kB signal transduction pathway dependent on the expression levels of EpoR. (f) Western blot analysis using total cellular lysates from HeLa TetOff-EpoR cells 48 h after the start of incubation at tetracycline concentrations from 0 to 1 mg/ml. Although NF-kB was strongly activated, IkBa protein levels remained unchanged. (g) Preincubation with the proteasome inhibitor MG132 (50 mM) did not prevent EpoR-mediated activation of NF-kB (lanes 1-8: HeLa TetOff-EpoR cells 48 h after the start of incubation at tetracycline concentrations from 0 to 1 mg/ml; lane 9: negative control demonstrating the specificity of the binding reaction). (h) Immune precipitation of total cellular lysates from HeLa TetOffEpoR cells after incubation at 1000, 25, 6 and 0 ng/ml tetracycline for 48 h using an antibody against IkBa. Western blotting using an antibody against phospho-tyrosine showed an increase in IkBa tyrosine phosphorylation at maximum expression of EpoR (lane 1)
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To investigate Epo/EpoR-dependent NF-kB activity, HeLa-TetOff-EpoR cells were plated into Petri dishes and regular media were replaced by tetracycline-free media. After 48 h, the media were supplemented with rhEpo (25 U/ml, Jannsen-Cilag). After 5 h, cells were harvested and NF-kB activity was monitored using EMSAs. EMSAs with total cellular extracts revealed a strong increase of NF-kB DNA-binding activity (Figure 1e ). However, this activation of NF-kB was not accomplished by proteasome-dependent degradation of IkBa since IkBa levels remained unchanged (Figure 1f ) and activation of NF-kB was not prevented by the proteasome inhibitor MG-132 (Figure 1g) . Immune precipitation using an antibody against IkBa and subsequent Western blotting against phosphotyrosine detected an increase in tyrosine-phosphorylated IkBa at least after maximum expression of EpoR (lane 1, Figure 1h ). Thus, activation of NF-kB was most likely a result of tyrosine phosphorylation-mediated dissociation of IkBa from the NF-kB complex, which has been previously described for vanadate treatment (Imbert et al., 1996) .
Activation of the Epo/EpoR-signal transduction pathway increases clonogenicity of HeLa cervical cancer cells
As mentioned earlier, the role of NF-kB in determining intrinsic radiation sensitivity of tumor cells is not clear. Most data that show protective effects of NF-kB result from experiments that did not exclude selection artefacts. On the contrary, data from Jung et al. (1995) indicate a possible contribution of NF-kB activation to radiation hypersensitivity of fibroblasts from patients suffering from ataxia teleangiectasia, while we excluded any role of NF-kB for the radiation sensitivity of PC-3 prostate cancer and HD-MyZ Hodgkin's lymphoma cells (Pajonk et al., 1999) .
The Epo/EpoR pathway and cancer cell survival F Pajonk et al NF-kB-mediated neuroprotection against oxidative stress described by Digicaylioglu et al. implied a possible radioprotection by EpoR signaling in EpoR-expressing tumor cells. In order to test this hypothesis, we performed clonogenic assays using HeLa-TetOff-EpoR cells. Therefore, cells were plated into Petri dishes and maintained in media containing 0 and 1 mg/ml tetracycline for 24 h. After 24 h, erythropoietin was added at 0 units/ml and 25 units/ml. After additional 24 h, cells were trypsinized, diluted and irradiated. In tetracyclinetreated, EpoR-negative cells, addition of Epo did not change the plating efficacy (Figure 2a , control: 37.374%; Epo-treated: 34.274.6%; not significant, two-sided Student's t-test, n ¼ 15). On the contrary in EpoR-expressing cells, Epo-treatment increased the plating efficacy more than 50% as compared to untreated cells (control: 30.874.2%; Epo-treated: 47.973.7% (Figure 2a , n ¼ 15, P ¼ 0.007, two-sided Student's t-test). In order to investigate a possible impact of Epo/EpoR signal transduction on radiation sensitivity, cells were irradiated with 0, 2, 4, 6 and 8 Gy, respectively, at a dose rate of 0.78 Gy/min. Surviving fraction of cells at each dose point was normalized with the corresponding unirradiated control. Analysis of clonogenic survival after irradiation could not detect any difference in intrinsic radiation sensitivity between rhEpo-treated and control cells (Figure 2b ).
Summary
Taken together, we showed that we established an in vitro model system in which stable-transfected HeLa cervical cancer cells express wild-type EpoR under control of tetracycline-responsive element. EpoR mRNA and protein expression in this system could be regulated over a wide range. The induced EpoR gene product was externalized as a transmembrane receptor protein and activated the downstream STAT 5 transcription factor in a regular manner.
Using this system we showed that rhEpo crossactivated the antiapoptotic NF-kB signal transduction pathway in EpoR-expressing tumor cells, which is the proposed underlying molecular mechanism of Eporelated cytoprotection from oxidative damage in normal tissues (Digicaylioglu and Lipton, 2001) . Comparable findings were published by Batr et al. (2003) for pediatric tumors. Interestingly, activation of NF-kB was not accomplished by degradation of its inhibitor molecule IkBa, since total amounts of IkBa protein remained stable and inhibition of proteasome function by MG-132 was not sufficient to prevent activation of NF-kB. Our findings are in accordance with the observation of Digicaylioglu and Lipton (2001) postulating a Jak2-dependent phosphorylation event to be the mechanism of NF-kB crossactivation by the Epo/EpoR pathway and offer the possibility that the tyrosine kinase Jak2 acts on IkBa directly. It was no surprise that activation of NF-kB signal transduction pathway did not alter the intrinsic radiation sensitivity of EpoRexpressing HeLa cells. This is in accordance with our earlier study showing no effect of NF-kB DNA-binding activity on intrinsic radiation sensitivity in PC-3 prostate cancer and HD-MyZ Hodgkin's lymphoma cells (Pajonk et al., 1999) . Lack of any impact of the EpoR Figure 2 HeLa-TetOff-EpoR cells were trypsinized, counted and diluted to a concentration of 10 6 cells/ml. The cell suspension was immediately irradiated at room temperature using a 137 Cslaboratory irradiator (IBL 637, CIS bio international) at a dose rate of 0.78 Gy/min). Corresponding controls were sham irradiated. Colony-forming assays were performed immediately after irradiation by plating an appropriate number of cells into Petri dishes, in triplicate. After 14 days, cells were fixed, stained with crystal violet, and colonies consisting of more than 50 cells were counted. Resulting survival plots were fitted using a linearquadratic model (Albright, 1987) . (a) Clonogenicity of EpoRexpressing (0 mg/ml tetracycline) and EpoR-nonexpressing (1 mg/ml tetracycline) HeLa TeOff-EpoR cells in the presence or absence of Epo (25 U/ml). In tetracycline-treated, EpoR-negative cells, rhEpo did not change the plating efficacy ( Figure 2a , control: 37.374%; Epo-treated: 34.274.6%; not significant, Student's t-test, n ¼ 15). In contrary, in EpoR-expressing cells, rhEpo treatment increased the plating efficacy more than 50% compared to untreated cells (control: 30.874.2%; Epo-treated: 47.973.7% (Figure 2a , n ¼ 15, Po0.01, Student's t-test)). (b) Results from clonogenic assays (n ¼ 15, each carried out in triplicates) using EpoR-expressing (0 mg/ml tetracycline) and EpoR-nonexpressing (1 mg/ml tetracycline) HeLa TeOff-EpoR cells in the presence or absence of Epo (25 U/ml). EpoR signaling did not change the intrinsic radiosensitivity of HeLa cells
The Epo/EpoR pathway and cancer cell survival F Pajonk et al signaling pathway on intrinsic radiation sensitivity is also in accordance with an earlier report investigating the effects of Epo in hematopoetic cell lines (Santucci et al., 1994) . In this study, the authors did not see any sensitizing effect of Epo if cells were irradiated at dose rates used in clinical settings. However, we found a more than 50% increase in the number of clonogenic tumor cells if HeLa cells expressed EpoR and were stimulated with rhEpo as compared to EpoR-nonexpressing tumor cells. This result does not contradict our data on intrinsic radiation sensitivity, since survival in clonogenic assays after irradiation is normalized to the corresponding number of surviving clones of unirradiated cells and thus independent of alterations in clonogenicity.
It is almost self-speaking that such an increase of the number of tumor stem cells has an impact on treatment outcome in vivo. Mathematical modeling (Suwinski et al., 1999) of 5000 hypothetical patients with T3 squamous cell carcinoma, with tumors exhibiting heterogeneity in a number of tumor stem cells, tumor doubling time and surviving fraction at 2 Gy estimated a loss of 12% of local control probability caused by twice-weekly rhEpo treatment during standard radiation therapy of 70 Gy given in 2 Gy fraction, assuming that half of the tumor cells express EpoR. This estimation is in accordance with our clinical data of a recently analysed multicenter trial applying rhEpo in anemic patients suffering from advanced head and neck cancer (Henke et al., 2003) .
Assuming that our in vitro data sufficiently reflects the situation in vivo, we conclude that application of rhEpo to anemic cancer patients undergoing radiation treatment should only be performed in controlled clinical trials. The specific inhibition of the Epo/EpoR signaling pathway in EpoR-expressing cancers could offer a promising new approach to improve local tumor control and survival in these patients.
